Document Detail


Anti-carcinogenic effects of sulforaphane in association with its apoptosis-inducing and anti-inflammatory properties in human cervical cancer cells.
MedLine Citation:
PMID:  20956097     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The multistep process of carcinogenesis is characterized by progressive disorganization and occurrence of initiation, promotion, and progression events. Several new strategies such as chemoprevention are being developed for treatment and prevention at various stages of carcinogenesis. Sulforaphane, a potential chemopreventive agent, possesses anti-proliferative, anti-inflammatory, anti-oxidant and anti-cancer activities and has attracted extensive interest for better cancer management.
METHODS: We evaluated the effect of sulforaphane alone or in combination with gemcitabine on HeLa cells by cell viability assay and confirmed the results by apoptosis assay. Further we analyzed the effect of sulforaphane on the expression of Bcl-2, COX-2 and IL-1β by RT-PCR on HeLa cells.
RESULTS: In the present study, sulforaphane was found to induce dose-dependent selective cytotoxicity in HeLa cells in comparison to normal cells pointing to its safe cytotoxicity profile. Additionally, a combination of sulforaphane and gemcitabine was found to increase the growth inhibition in a synergistic manner in HeLa cells compared to the individual drugs. Also, the expression analysis of genes involved in apoptosis and inflammation revealed significant downregulation of Bcl-2, COX-2 and IL-1β upon treatment with sulforaphane.
CONCLUSION: Our results suggest that sulforaphane exerts its anticancer activities via apoptosis induction and anti-inflammatory properties and provides the first evidence demonstrating synergism between sulforaphane and gemcitabine which may enhance the therapeutic index of prevention and/or treatment of cervical cancer.
Authors:
Chhavi Sharma; Lida Sadrieh; Anita Priyani; Musthaq Ahmed; Ahmad H Hassan; Arif Hussain
Related Documents :
11340567 - Radiation-induced apoptosis in human myeloma cell line increases bcl-2/bax dimer format...
19669197 - Apoptosis of t(14;18)-positive lymphoma cells by a bcl-2 interacting small molecule.
11229367 - Redox aspects of bcl-2 function.
25165887 - Host responses to group a streptococcus: cell death and inflammation.
1937887 - Airway inflammation and atopic asthma: a comparative bronchoscopic investigation.
20508727 - Nonintegrating lentiviral vector-based vaccine efficiently induces functional and persi...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-10-16
Journal Detail:
Title:  Cancer epidemiology     Volume:  35     ISSN:  1877-783X     ISO Abbreviation:  Cancer Epidemiol     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-05-20     Completed Date:  2011-09-13     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  101508793     Medline TA:  Cancer Epidemiol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  272-8     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Ltd. All rights reserved.
Affiliation:
Department of Biotechnology, Manipal University, Dubai, United Arab Emirates.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticarcinogenic Agents / administration & dosage,  pharmacology*
Antimetabolites, Antineoplastic / pharmacology
Apoptosis / drug effects*
Cell Survival / drug effects
Cyclooxygenase 2 / genetics
Deoxycytidine / analogs & derivatives,  pharmacology
Dose-Response Relationship, Drug
Down-Regulation / drug effects
Drug Synergism
Female
Gene Expression Regulation, Neoplastic
HeLa Cells
Humans
Inflammation / drug therapy,  pathology
Interleukin-1beta / genetics
Proto-Oncogene Proteins c-bcl-2 / genetics
Reverse Transcriptase Polymerase Chain Reaction
Thiocyanates / administration & dosage,  pharmacology*
Uterine Cervical Neoplasms / drug therapy*,  pathology
Chemical
Reg. No./Substance:
0/Anticarcinogenic Agents; 0/Antimetabolites, Antineoplastic; 0/Interleukin-1beta; 0/Proto-Oncogene Proteins c-bcl-2; 0/Thiocyanates; 4478-93-7/sulforafan; 951-77-9/Deoxycytidine; B76N6SBZ8R/gemcitabine; EC 1.14.99.1/Cyclooxygenase 2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Should diabetes be commissioned through multidisciplinary networks, rather than Practice Based Commi...
Next Document:  Rituximab for primary cutaneous diffuse large B-cell lymphoma-leg type.